Solid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Walleye Capital LLC

Walleye Capital LLC trimmed its position in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 59.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 158,831 shares of the company's stock after selling 233,270 shares during the quarter. Walleye Capital LLC owned approximately 0.40% of Solid Biosciences worth $635,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Solid Biosciences by 9,393.8% during the 4th quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock valued at $3,824,000 after acquiring an additional 945,863 shares in the last quarter. Rhumbline Advisers raised its position in shares of Solid Biosciences by 10.5% during the 4th quarter. Rhumbline Advisers now owns 43,677 shares of the company's stock valued at $175,000 after acquiring an additional 4,161 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Solid Biosciences by 4.0% during the 4th quarter. Wellington Management Group LLP now owns 124,551 shares of the company's stock valued at $498,000 after acquiring an additional 4,747 shares in the last quarter. Barclays PLC raised its position in shares of Solid Biosciences by 412.1% during the 3rd quarter. Barclays PLC now owns 62,856 shares of the company's stock valued at $439,000 after acquiring an additional 50,582 shares in the last quarter. Finally, Prudential Financial Inc. raised its position in shares of Solid Biosciences by 71.3% during the 4th quarter. Prudential Financial Inc. now owns 109,105 shares of the company's stock valued at $436,000 after acquiring an additional 45,400 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences Price Performance

Shares of NASDAQ SLDB traded down $0.07 during midday trading on Monday, reaching $3.23. 675,210 shares of the company traded hands, compared to its average volume of 935,526. Solid Biosciences Inc. has a 52 week low of $2.45 and a 52 week high of $10.99. The stock has a 50-day moving average price of $4.18 and a 200 day moving average price of $4.48. The company has a market cap of $250.30 million, a price-to-earnings ratio of -1.06 and a beta of 2.07.

Analyst Ratings Changes

SLDB has been the topic of several research reports. HC Wainwright upped their price target on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Chardan Capital reaffirmed a "buy" rating and issued a $16.00 target price on shares of Solid Biosciences in a research report on Friday, March 7th. Truist Financial initiated coverage on Solid Biosciences in a research report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, JPMorgan Chase & Co. dropped their target price on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $15.67.

Solid Biosciences Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.